11:59 AM EDT, 09/09/2024 (MT Newswires) -- Regeneron Pharmaceuticals' ( REGN ) Factor XI antibodies are poised to "generate more attention" given their promising target, differentiated features and large market opportunity, RBC Capital Markets said in a Monday note.

RBC said its analysis of the Factor XI program and the anticoagulant landscape highlighted positive factors for Regeneron such as the binding affinity results of its antibodies, their potential in reducing the risks of bleeding, pulmonary embolism, and deep vein thrombosis, and opportunities to expand its market.

"Overall, we believe Factor XI provides overlooked optionality for another major blockbuster program," RBC said, noting that potential risks include a crowded market and effective standard of care.

The program's REGN9933 and REGN7508 product candidates are currently under phase 2 studies and according to RBC, Regeneron plans to expedite both to phase 3 trials.

RBC Capital Markets maintained its outperform rating on Regeneron Pharmaceuticals ( REGN ), with a higher price target of $1,282 from $1,250 previously.

Price: 1144.47, Change: +12.97, Percent Change: +1.15